Stage IA NSCLC Cohort

Cross-source consensus on Stage IA NSCLC Cohort from 1 sources and 5 claims.

1 sources · 5 claims

Evidence quality

The main study population is patients diagnosed with stage IA NSCLC in Germany from 2016 to 2023. — Stereotactic ablative radiotherapy versus video-assisted lobectomy for operable stage I non-small-cell lung cancer: study protocol for an emulated target trial
The emulated trial includes only patients eligible for both SABR and VATS at baseline to preserve positivity. — Stereotactic ablative radiotherapy versus video-assisted lobectomy for operable stage I non-small-cell lung cancer: study protocol for an emulated target trial
The Charlson Comorbidity Index will be calculated for every included patient and used in statistical adjustment. — Stereotactic ablative radiotherapy versus video-assisted lobectomy for operable stage I non-small-cell lung cancer: study protocol for an emulated target trial
Eligibility criteria aim to represent a setting where both treatment strategies would have been viable. — Stereotactic ablative radiotherapy versus video-assisted lobectomy for operable stage I non-small-cell lung cancer: study protocol for an emulated target trial
PET/CT is required to confirm stage and nodal involvement for eligibility. — Stereotactic ablative radiotherapy versus video-assisted lobectomy for operable stage I non-small-cell lung cancer: study protocol for an emulated target trial